Why Gilead had to play the dividend card
This article was originally published in Scrip
After posting yet another quarter of record-breaking profits on 30 April, Gilead Sciences announced that it would disperse $670m or so of those profits to shareholders in June in its first ever dividend payment. That might be an act of commercial maturity, a sign that Gilead is courting investors who are looking for both growth and dividend yield. Or it could be an act of defiance, a message from management to critics of the company's profits, ethics and transparency that Gilead plans to continue to plough its own commercial furrow.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.